在膀癌中治疗反应的代谢特征
Tiago Vieira de Sousa1,2, Paula Guedes de Pinho1,2, Joana Pinto1,2
1Associate Laboratory i4HB-Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal.
International journal of molecular sciences
|December 23, 2023
概括
代谢学提供了通过识别独特的代谢变化来跟踪膀癌 (BC) 治疗有效性的新方法. 这种方法有助于预测患者的结果,并为更好的膀癌管理提供个性化的药物.
科学领域:
- 尿瘤学 尿瘤学
- 翻译医学是一种翻译医学.
- 生物标志物发现发现
背景情况:
- 膀癌 (BC) 是一种常见的尿道恶性瘤,具有显著的复发率.
- 目前的手术,化疗和免疫疗法等治疗方法在治疗侵袭性BC时存在局限性.
- 精确监测治疗反应对于改善患者的治疗结果至关重要.
研究的目的:
- 审查代谢化学的应用,以了解膀癌的治疗反应.
- 探索来自新陈代谢的生物标志物在BC个性化医疗的潜力.
- 突出代谢物水平的变化作为治疗疗效的指标.
主要方法:
- 综合性文献综述使用代谢化学物质用于BC治疗反应的研究.
- 在代谢学研究中分析各种模型,样本类型和分析技术.
- 专注于识别和评估与不同BC疗法相关的代谢物水平变化.
主要成果:
- 代谢学揭示了与BC治疗反应相关的特定代谢干扰.
- 识别的代谢物变化可以作为监测治疗疗效的潜在生物标志物.
- 该审查涵盖了用于膀癌的各种代谢学方法.
结论:
- 代谢学提出了一个有前途的战略,用于发现生物标志物来监测和预测BC治疗反应.
- 这种方法可以显著提高膀癌治疗的个性化.
- 对代谢生物标志物的进一步研究可能会彻底改变BC管理和患者护理.
更多相关视频
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


